SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel ...

(RTTNews) - Organovo Holdings, Inc. (ONVO), a clinical-stage biotech firm focused on advancing innovative treatments for inflammatory bowel disease, on Monday announced the appointment of Norman ...

Shares of NASDAQ ONVO opened at $0.37 on Friday. Organovo has a 12 month low of $0.32 and a 12 month high of $1.74. The company has a market cap of $5.69 million, a price-to-earnings ratio of -0. ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Organovo Holdings, Inc. (NASDAQ:ONVO), a biotech firm specializing in biological products with a current market capitalization of just $5.92 million, announced on Thursday that it has received a ...

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel ...

Organovo Holdings, Inc. appointed Norman Staskey as the new President, Chief Financial Officer, and Principal Financial Officer following the resignation of Tomas Hess, who left to pursue retirement.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...